publication . Article . 2019

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate

Ken Lee Chin; Timothy Collier; Stuart Pocock; Bertram Pitt; John J. V. McMurray; Dirk J. van Veldhuisen; Karl Swedberg; John Vincent; Faiez Zannad; Danny Liew;
Closed Access English
  • Published: 01 Jul 2019
  • Country: United Kingdom
Background: Increased resting heart rate is a risk factor for cardiovascular mortality and morbidity. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve cardiac sympathetic nerve activity, reduce heart rate and attenuate left ventricular remodelling. Whether or not the beneficial effects of MRA are affected by heart rate in heart failure patients with reduced ejection fraction (HFREF) is unclear. Methods: We undertook a secondary analysis of data from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure study to assess if clinical outcomes, as well as the efficacy of eplerenone, varied according to heart rate ...
free text keywords: ClinicalTrials, gov identifier: NCT00232180, Heart rate, Aldosterone antagonists, Aldosterone, Heart failure, REDUCED EJECTION FRACTION, MILD PATIENTS HOSPITALIZATION, ATRIAL-FIBRILLATION, COST-EFFECTIVENESS, RISK, SPIRONOLACTONE, ASSOCIATION, IVABRADINE, SURVIVAL, Cardiology and Cardiovascular Medicine, General Medicine, chemistry.chemical_compound, chemistry, Ejection fraction, Internal medicine, medicine.medical_specialty, medicine, Risk factor, Atrial fibrillation, medicine.disease, business.industry, business, medicine.drug, Eplerenone, Cardiology
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue